Cargando…
Establishment and characterization of arsenic trioxide resistant KB/ATO cells
Arsenic trioxide (ATO) is used as a chemotherapeutic agent for the treatment of acute promyelocytic leukemia. However, increasing drug resistance is reducing its efficacy. Therefore, a better understanding of ATO resistance mechanism is required. In this study, we established an ATO-resistant human...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595296/ https://www.ncbi.nlm.nih.gov/pubmed/28924550 http://dx.doi.org/10.1016/j.apsb.2017.04.001 |
_version_ | 1783263345449631744 |
---|---|
author | Zhang, Yun-Kai Dai, Chunling Yuan, Chun-gang Wu, Hsiang-Chun Xiao, Zhijie Lei, Zi-Ning Yang, Dong-Hua Le, X. Chris Fu, Liwu Chen, Zhe-Sheng |
author_facet | Zhang, Yun-Kai Dai, Chunling Yuan, Chun-gang Wu, Hsiang-Chun Xiao, Zhijie Lei, Zi-Ning Yang, Dong-Hua Le, X. Chris Fu, Liwu Chen, Zhe-Sheng |
author_sort | Zhang, Yun-Kai |
collection | PubMed |
description | Arsenic trioxide (ATO) is used as a chemotherapeutic agent for the treatment of acute promyelocytic leukemia. However, increasing drug resistance is reducing its efficacy. Therefore, a better understanding of ATO resistance mechanism is required. In this study, we established an ATO-resistant human epidermoid carcinoma cell line, KB/ATO, from its parental KB-3-1 cells. In addition to ATO, KB/ATO cells also exhibited cross-resistance to other anticancer drugs such as cisplatin, antimony potassium tartrate, and 6-mercaptopurine. The arsenic accumulation in KB/ATO cells was significantly lower than that in KB-3-1 cells. Further analysis indicated that neither application of P-glycoprotein inhibitor, breast cancer resistant protein (BCRP) inhibitor, or multidrug resistance protein 1 (MRP1) inhibitor could eliminate ATO resistance. We found that the expression level of ABCB6 was increased in KB/ATO cells. In conclusion, ABCB6 could be an important factor for ATO resistance in KB/ATO cells. The ABCB6 level may serve as a predictive biomarker for the effectiveness of ATO therapy. |
format | Online Article Text |
id | pubmed-5595296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-55952962017-09-18 Establishment and characterization of arsenic trioxide resistant KB/ATO cells Zhang, Yun-Kai Dai, Chunling Yuan, Chun-gang Wu, Hsiang-Chun Xiao, Zhijie Lei, Zi-Ning Yang, Dong-Hua Le, X. Chris Fu, Liwu Chen, Zhe-Sheng Acta Pharm Sin B Original Article Arsenic trioxide (ATO) is used as a chemotherapeutic agent for the treatment of acute promyelocytic leukemia. However, increasing drug resistance is reducing its efficacy. Therefore, a better understanding of ATO resistance mechanism is required. In this study, we established an ATO-resistant human epidermoid carcinoma cell line, KB/ATO, from its parental KB-3-1 cells. In addition to ATO, KB/ATO cells also exhibited cross-resistance to other anticancer drugs such as cisplatin, antimony potassium tartrate, and 6-mercaptopurine. The arsenic accumulation in KB/ATO cells was significantly lower than that in KB-3-1 cells. Further analysis indicated that neither application of P-glycoprotein inhibitor, breast cancer resistant protein (BCRP) inhibitor, or multidrug resistance protein 1 (MRP1) inhibitor could eliminate ATO resistance. We found that the expression level of ABCB6 was increased in KB/ATO cells. In conclusion, ABCB6 could be an important factor for ATO resistance in KB/ATO cells. The ABCB6 level may serve as a predictive biomarker for the effectiveness of ATO therapy. Elsevier 2017-09 2017-04-28 /pmc/articles/PMC5595296/ /pubmed/28924550 http://dx.doi.org/10.1016/j.apsb.2017.04.001 Text en © 2017 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Zhang, Yun-Kai Dai, Chunling Yuan, Chun-gang Wu, Hsiang-Chun Xiao, Zhijie Lei, Zi-Ning Yang, Dong-Hua Le, X. Chris Fu, Liwu Chen, Zhe-Sheng Establishment and characterization of arsenic trioxide resistant KB/ATO cells |
title | Establishment and characterization of arsenic trioxide resistant KB/ATO cells |
title_full | Establishment and characterization of arsenic trioxide resistant KB/ATO cells |
title_fullStr | Establishment and characterization of arsenic trioxide resistant KB/ATO cells |
title_full_unstemmed | Establishment and characterization of arsenic trioxide resistant KB/ATO cells |
title_short | Establishment and characterization of arsenic trioxide resistant KB/ATO cells |
title_sort | establishment and characterization of arsenic trioxide resistant kb/ato cells |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595296/ https://www.ncbi.nlm.nih.gov/pubmed/28924550 http://dx.doi.org/10.1016/j.apsb.2017.04.001 |
work_keys_str_mv | AT zhangyunkai establishmentandcharacterizationofarsenictrioxideresistantkbatocells AT daichunling establishmentandcharacterizationofarsenictrioxideresistantkbatocells AT yuanchungang establishmentandcharacterizationofarsenictrioxideresistantkbatocells AT wuhsiangchun establishmentandcharacterizationofarsenictrioxideresistantkbatocells AT xiaozhijie establishmentandcharacterizationofarsenictrioxideresistantkbatocells AT leizining establishmentandcharacterizationofarsenictrioxideresistantkbatocells AT yangdonghua establishmentandcharacterizationofarsenictrioxideresistantkbatocells AT lexchris establishmentandcharacterizationofarsenictrioxideresistantkbatocells AT fuliwu establishmentandcharacterizationofarsenictrioxideresistantkbatocells AT chenzhesheng establishmentandcharacterizationofarsenictrioxideresistantkbatocells |